GU Cancers 2020 | Bladder: minimizing recurrence with cetuximab

Name: Bladder: minimizing recurrence with cetuximab
Uploaded: 2020-02-15T00:18:56Z
Description: Nicholas James, MBBS, PhD, FRCP, FRCR, The Institute of Cancer Research, London, UK, discusses his phase I/II study of cetuximab in addition to radiotherapy and/or chemotherapy in muscle-invasive bladder cancer at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Nicholas James • 15 Feb 2020

GU Cancers 2020

Bladder Cancer Genitourinary Cancer Antibodies Cetuximab Cisplatin

Nicholas James, MBBS, PhD, FRCP, FRCR, The Institute of Cancer Research, London, UK, discusses his phase I/II study of cetuximab in addition to radiotherapy and/or chemotherapy in muscle-invasive bladder cancer at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.